Skip to main content
Premium Trial:

Request an Annual Quote

Teva to Distribute Three Rosetta Genomics Tests

NEW YORK (GenomeWeb News) — Rosetta Genomics has inked an agreement under which Teva Pharmaceutical Industries will distribute three of the company’s microRNA-based molecular diagnostic cancer tests in Israel and Turkey.
 
Rosetta Genomics Chief Commercialization Officer Ronen Tamir said that because Israel has provided its citizens with health insurance under the National Health Law it is “a very attractive market,” adding that Turkey is “a country with significant market potential.”
 
The three tests covered under the agreement are from the company’s miRview line, including miRview Mets, miRview Squamous, and miRview Meso. The miRview Mets test identifies the primary tumor site in patients with metastatic cancer, and in those whose tumors have been labeled cancer of unknown primary. The squamous test differentiates squamous from non-squamous, non-small cell lung cancer patients. The meso test differentiates mesothelioma from other carcinomas found in the lung.
 
Financial terms of the agreement were not released.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.